CCND1 and non-small cell lung carcinoma: PPAR-γ-selective agonists such as ciglitazone and 15D-PGJ2 have diminished the growth of non-small cell lung cancer (NSCLC) cells through the induction of apoptosis, promotion of differentiation and the down-regulation of cell cycle proteins such as Cyclin D1 [35,37].